Eylea Injection Prefilled Syringe Is Now Available

By

Product: Eylea (aflibercept) Injection Prefilled Syringe
Top Line: Regeneron’s Eylea (aflibercept) Injection prefilled syringe, an anti-VEGF treatment that received FDA approval for in August, 2019, is now available for doctors to order.
Close Up: The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer EYLEA that requires fewer preparation steps compared to vials.
EYLEA is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe. In the U.S., Eylea is indicated to treat neovascular (wet) age-related macular degeneration (Wet AMD) with dosing options every 4 or 8 weeks following an initial monthly dosing period or 12 weeks after one year of effective therapy, and for all stages of diabetic retinopathy (DR) and Diabetic Macular Edema (DME) every 4 or 8 weeks, following an initial dosing period.
Vital Stats: Eylea (aflibercept) Injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. It is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PLGF), two growth factors involved in angiogenesis. In the U.S., EYLEA is the market-leading, FDA-approved anti-VEGF treatment for its approved indications and is supported by a robust body of research that includes eight pivotal Phase 3 trials.
www.regeneron.com/eylea-injection